KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Assets (2016 - 2025)

Eli Lilly's Assets history spans 17 years, with the latest figure at $112.5 billion for Q4 2025.

  • For Q4 2025, Assets rose 42.89% year-over-year to $112.5 billion; the TTM value through Dec 2025 reached $112.5 billion, up 42.89%, while the annual FY2025 figure was $112.5 billion, 42.89% up from the prior year.
  • Assets reached $112.5 billion in Q4 2025 per LLY's latest filing, down from $114.9 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $114.9 billion in Q3 2025 to a low of $46.8 billion in Q1 2021.
  • Average Assets over 5 years is $66.0 billion, with a median of $56.4 billion recorded in 2023.
  • Peak YoY movement for Assets: fell 1.56% in 2022, then surged 52.02% in 2025.
  • A 5-year view of Assets shows it stood at $48.8 billion in 2021, then grew by 1.4% to $49.5 billion in 2022, then rose by 29.33% to $64.0 billion in 2023, then rose by 22.98% to $78.7 billion in 2024, then soared by 42.89% to $112.5 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Assets are $112.5 billion (Q4 2025), $114.9 billion (Q3 2025), and $100.9 billion (Q2 2025).